Solid Biosciences, Inc. (SLDB)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$5.92-4.36%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Solid Biosciences, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	0
EPS	—	-0.421
Annual ending 2026-12-31
Revenue	—	3.68M
EPS	—	-1.739
Annual ending 2027-12-31
Revenue	—	10.31M
EPS	—	-1.693

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Progress in Phase 1/2 INSPIRE DUCHENNE trial for SGT-003	Solid Biosciences is working on a new drug for Duchenne muscular dystrophy.	Improving	trial data shows safety or efficacy issues	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Fund operations into first half of 2028	It raised money to fund operations into 2028.	Intact	cash runway falls short of H1 2028	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Reduce net losses toward breakeven	A supporting condition in Solid Biosciences, Inc.'s published investment case. The stated target is EPS loss narrows from -$1.96 in 2026 to less negative in 2027.	Intact	EPS loss worsens beyond -$1.96 in 2027	Diluted EPS: $-0.38 per share FY2026-Q2; GAAP. Published target: EPS loss narrows from -$1.96 in 2026 to less negative in 2027. Target period is not explicitly aligned with this observation. Source published Aug 6, 2026-0.38 USD/share · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 49394ba5-9f8e-4b7c-967c-5e704416725f. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-1.69

$-1.93 → $-1.69 · observed estimates

FY2027 revenue$0.01B

$0.01B → $0.01B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-1.93	$13,299,862	10 / 8
2026-07-25	$-1.93	$13,299,862	10 / 8
2026-07-26	$-1.93	$13,299,862	10 / 8
2026-07-27	$-1.93	$13,299,862	10 / 8
2026-07-28	$-1.93	$13,299,862	10 / 8
2026-07-29	$-1.96	$11,084,300	12 / 12
2026-07-30	$-1.93	$13,299,862	10 / 8
2026-07-31	$-1.96	$11,084,300	12 / 12
2026-08-01	$-1.93	$13,299,862	10 / 8
2026-08-02	$-1.96	$11,084,300	12 / 12
2026-08-03	$-1.93	$13,299,862	10 / 8
2026-08-04	$-1.93	$13,299,862	10 / 8
2026-08-05	$-1.93	$13,299,862	10 / 8
2026-08-06	$-1.93	$13,299,862	10 / 8
2026-08-08	$-1.96	$11,084,300	12 / 12
2026-08-09	$-1.93	$13,299,862	10 / 8
2026-08-10	$-1.96	$11,084,300	12 / 12
2026-08-12	$-1.93	$13,299,862	10 / 8
2026-08-13	$-1.93	$13,299,862	10 / 8
2026-08-14	$-1.93	$13,299,862	10 / 8
2026-08-15	$-1.93	$13,299,862	10 / 7
2026-08-16	$-1.93	$13,299,862	10 / 7
2026-08-17	$-1.93	$13,299,862	10 / 7
2026-08-18	$-1.93	$13,299,862	10 / 8
2026-08-19	$-1.93	$13,299,862	10 / 8
2026-08-20	$-1.75	$11,953,727	10 / 7
2026-08-21	$-1.75	$11,953,727	10 / 7
2026-08-22	$-1.75	$11,953,727	10 / 7
2026-08-23	$-1.75	$11,953,727	10 / 8
2026-08-24	$-1.75	$11,953,727	10 / 8
2026-08-25	$-1.75	$11,953,727	10 / 8
2026-08-26	$-1.75	$11,953,727	10 / 8
2026-08-27	$-1.75	$11,953,727	10 / 8
2026-08-28	$-1.75	$11,953,727	10 / 8
2026-08-29	$-1.75	$11,953,727	10 / 8
2026-08-30	$-1.75	$11,953,727	10 / 8
2026-08-31	$-1.75	$11,953,727	10 / 8
2026-09-01	$-1.75	$11,953,727	10 / 8
2026-09-02	$-1.75	$11,953,727	10 / 8
2026-09-03	$-1.75	$11,953,727	10 / 8
2026-09-04	$-1.75	$11,953,727	10 / 8
2026-09-05	$-1.75	$11,953,727	10 / 8
2026-09-06	$-1.75	$11,953,727	10 / 8
2026-09-07	$-1.75	$11,953,727	10 / 8
2026-09-08	$-1.75	$11,953,727	10 / 8
2026-09-09	$-1.75	$11,953,727	10 / 8
2026-09-10	$-1.75	$11,953,727	10 / 8
2026-09-11	$-1.75	$11,953,727	10 / 8
2026-09-12	$-1.75	$11,953,727	10 / 8
2026-09-13	$-1.75	$11,953,727	10 / 8
2026-09-14	$-1.75	$11,953,727	10 / 8
2026-09-15	$-1.75	$11,953,727	10 / 8
2026-09-16	$-1.75	$11,953,727	10 / 8
2026-09-17	$-1.73	$11,953,727	10 / 8
2026-09-18	$-1.73	$11,953,727	10 / 8
2026-09-19	$-1.73	$11,953,727	10 / 8
2026-09-20	$-1.73	$11,953,727	11 / 9
2026-09-21	$-1.73	$11,953,727	11 / 9
2026-09-22	$-1.73	$11,953,727	11 / 9
2026-09-23	$-1.73	$11,953,727	11 / 9
2026-09-24	$-1.73	$11,953,727	11 / 9
2026-09-25	$-1.73	$11,953,727	10 / 8
2026-09-26	$-1.70	$11,470,808	10 / 8
2026-09-27	$-1.70	$11,470,808	10 / 8
2026-09-28	$-1.70	$11,470,808	10 / 8
2026-09-29	$-1.70	$11,470,808	10 / 8
2026-09-30	$-1.70	$11,470,808	10 / 8
2026-10-01	$-1.69	$11,470,808	10 / 8
2026-10-02	$-1.69	$11,470,808	10 / 8
2026-10-03	$-1.69	$11,470,808	10 / 8
2026-10-04	$-1.69	$11,470,808	10 / 8
2026-10-05	$-1.69	$11,470,808	10 / 8
2026-10-06	$-1.69	$11,470,808	10 / 8
2026-10-07	$-1.69	$11,470,808	10 / 8
2026-10-08	$-1.69	$11,470,808	10 / 8
2026-10-09	$-1.69	$11,470,808	10 / 8
2026-10-10	$-1.69	$11,470,808	10 / 8
2026-10-11	$-1.69	$11,470,808	10 / 8
2026-10-12	$-1.69	$11,470,808	10 / 8
2026-10-13	$-1.69	$11,470,808	10 / 8
2026-10-14	$-1.69	$11,470,808	10 / 8
2026-10-15	$-1.69	$11,470,808	10 / 8
2026-10-16	$-1.69	$10,323,727	11 / 8
2026-10-17	$-1.69	$10,323,727	11 / 8
2026-10-18	$-1.69	$10,323,727	11 / 8
2026-10-19	$-1.69	$10,323,727	11 / 8
2026-10-20	$-1.69	$10,323,727	11 / 8
2026-10-21	$-1.69	$10,313,727	11 / 8
2026-10-22	$-1.69	$10,313,727	11 / 8
2026-10-23	$-1.69	$10,313,727	11 / 8
2026-10-24	$-1.69	$10,313,727	11 / 8

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold	Sell*
2026-05-01	14	0	0
2026-06-01	14	0	0
2026-07-01	14	0	0
2026-08-01	13	0	0
2026-09-01	14	0	0
2026-10-01	14	0	0

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 14 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Progress in Phase 1/2 INSPIRE DUCHENNE trial for SGT-003Direct metric needs a verified mapping
Fund operations into first half of 2028Direct metric needs a verified mapping
Reduce net losses toward breakevenDiluted EPS: $-0.38 per share

Next proof point

Nov 2, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

3.0%Typical daily move · historical

Downside history

-50.9%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Solid Biosciences, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-stage biotechnology business, not an established earnings compounder. The long-term thesis is in a watch state: interim SGT-003 data are encouraging, but recent financial performance is weak and the evidence snapshot has low confidence.

What's priced into Solid Biosciences, Inc.

The snapshot provides no valuation comparison or clear account of market expectations, so whether SLDB is cheap or expensive versus peers cannot be assessed. No priced-in fragility flags fired, but that does not resolve the uncertainty around its losses, clinical progress, or funding needs.

What the fundamentals likely do

Near term, operating losses and cash burn remain elevated, and the company reported an earnings miss in March 2026. Management says private-placement proceeds plus existing cash are expected to fund operations into the first half of 2028, while positive interim SGT-003 data offer a clinical milestone; a next-call guidance cut remains a stated risk.

What Solid Biosciences, Inc. hinges on

Over the next one to three years, the thesis hinges on further progress in the SGT-003 trial and whether available funding can support operations into the stated 2028 horizon. Near-term results could be affected by guidance changes and broader sector conditions, while stronger earnings and guidance from healthcare bellwethers would support sector momentum.